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quantification the proper attenuation, scatter and 
partial volume corrections need to be applied. If organ 
or lesion dosimetry is performed, precise determination 
of organ/lesion volumes is necessary. Care has to be 
taken for an appropriate calibration of the imaging 
system. 
b) Biokinetics 
  This requires the determination of a correct temporal 
sampling and the use of ad hoc procedures to integrate 
the activity within time to obtain the total number of 
decays occurring in the source organs and thus the 
time-integrated activity coefficients (TIACs). 
c) Absorbed dose Calculation 
If the TIACs of the relevant structures are known, a 
calculation of the absorbed doses can be performed by 
applying, in most cases, the “MIRD formalism”: 
D = Ã*S 
D: the mean absorbed dose to a voxel or a target 
region from the cumulated activity in a source region. 
Ã: the cumulated activity (i.e. the integral of the 
time-activity curve) 
S: S factor (= mean absorbed dose per unit cumulated 
activity in the voxel or the target region).  
Different dose calculation approaches exist: These may 
either be based on tabulated S factors (with mass correction) 
of anthropomorphic phantoms, on convolution kernels or on 
Monte-Carlo simulations. 
Results: The most successful pairs of isotopes for theranostics 
are I-123/I-124/I-131 [2] and Ga-68/Lu-177/Y-90 [3]. In 
addition, Y-90 PET/CT provides a good estimate of the 
absorbed doses in selective internal radiotherapy for loco-
regional liver treatment [4]. 
 
Conclusion: Although many new radiopharmaceuticals are 
available for imaging and molecular radiotherapy it is still a 
challenge to establish reliable dose-response relationships.  
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Purpose: Auger-electron (AE) emitting radionuclides could be 
exploited for therapeutic purposes due to the high local 
energy deposition by low-energy Auger electrons or may 
deliver an unintentional mean absorbed dose burden when 
used as medical imaging agents. The aim of this study is to 
provide S-values for selected 14 AE emitting radionuclides 
based on the latest radiation spectra.  
Methods: The Monte Carlo code PENELOPE [1] was used to 
transport the complete radiation spectra of 67Ga, 80mBr, 89Zr, 
90Nb, 99mTc, 111In, 117mSn, 119Sb, 123I, 124I, 125I, 135La, 195mPt and 
201Tl using the methodology described in Ref. [2]. Radiation 
spectra was based on the unabridged nuclear decay data 
from MIRD RADTABS program [3] and the radiation spectra 
generated using the BrIccEmis code [4]. Taking the nucleus as 
the target, simulations were run assuming uniformly 
distributed activity in the nucleus (N←N), in the cytoplasm 
(N←Cy) or on the cell surface (N←CS).  
Results: A comparison of calculated Auger yields for all 14 
radionuclides is shown in the table below. Auger yields from 
MIRD are consistently higher than the values calculated using 
the BrIccEmis code. The methodology used to produce data 
in MIRD did not account for variations in binding energies 
during atomic relaxation thus overestimated the intensity of 
low-energy electrons.  
 
BrIccEmiss determined S-values were generally lower 
compared with MIRD S-values with the greatest differences 
noted when the source is far from the target region, i.e. for 
the N←Cy and N←CS configurations. 
Conclusions: Realistic modelling of atomic relaxation 
following nuclear decay is essential for producing the 
radiation spectra needed for the calculations of S-values.  
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Purpose: The local temperature increase induced by ion 
energy deposition in tissue creates an “ionoacoustic” 
ultrasound signal, particularly at the dose maximum (Bragg 
peak)[1-3]. This signal may be used for range verification in 
ion beam therapy in the future, which is still an important 
challenge for this irradiation modality. This approach has 
recently been revisited by several groups in simulations [4, 
5], and by our group in simulations and also in proof-of-
principle experiments with pulsed 20 MeV proton beams [6]. 
Here we present new simulations and first measurements of 
the ionoacoustic signal produced in water by proton beams 
accelerated up to energies of 227 MeV at a clinical synchro-
cyclotron. 
Material and Methods: In preparation of ionoacoustic 
experiments at clinically relevant energies, we extended our 
simulations from previously 20 MeV to beam energies of 120-
230 MeV. The propagation of ultrasound waves was simulated 
by the MATLAB toolbox k-Wave using Geant4 for calculations 
of the initial dose deposition. The corresponding 
experimental setup to measure the ionoacoustic signal 
consisted of a broadband hydrophone (500 Hz - 250 kHz) 
placed in a water phantom with protons entering through the 
water surface. We measured the transit time of the 
ionoacoustic signal from the Bragg peak to the hydrophone 
and varied this distance either by using different energies 
(227, 226 and 145 MeV) or by changing the detector position 
while using the maximum energy.  
Result: The simulations showed a distinct frequency shift of 
the ionoacoustic signal spectrum from a few MHz at 20 MeV 
from our previous experiments to about 100 kHz and below at 
proton beam energies above 120 MeV. At the new IBA 
synchro-cyclotron, we were able to measure ionoacoustic 
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signals from a pulsed proton beam (about 5 pC/pulse, 6 µs 
FWHM) and detector shifts down to 2 mm. The measured 
relative shifts of the Bragg peak position of 2.3 mm for 1 MeV 
energy change and 173.25 mm for 82 MeV are in perfect 
agreement with Geant4 predictions. However, the low signal 
amplitude below 1 mV required an averaging with 1024 
acquisitions. 
Conclusion: Measuring the ionoacoustic signal at the IBA 
synchro-cyclotron, the detectability of 2 mm range shifts 
could be demonstrated. Experimental upgrades will be 
discussed, from which we reasonably assume to improve the 
resolution to 1 mm and below. In order to determine an 
absolute ion range in water in future ionoacoustic 
experiments, a method using an additional ultrasound 
transducer to measure the distance of the hydrophone to the 
water surface was developed. Remaining challenges on signal 
detectability for clinical dose rates as well as perspectives of 
future setup improvements will be discussed. 
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Purpose: Online in vivo control of the ion range in a patient 
during proton therapy is a major challenge for quality 
assurance of treatments. After measurements showed that 
prompt-γ emission is correlated to the ion range (Min et al 
2006, Testa et al 2008), prompt-γ imaging emerged as a 
promising method (Verburg et al 2013). Fast methods are 
required to compute accurate prompt-γ emission maps to 
design and predict the camera response from treatment 
plans. An analytic computation method based on the 
structure of the dose calculation engines in treatment 
planning system has recently been proposed (Sterpin et al 
2015). An alternative technique based on variance reduction 
in Monte Carlo (MC) calculations is developed here for 
computing prompt-γ emission maps in proton therapy.  
Materials/Methods: The track length estimator (TLE) method 
is a standard variance reduction technique in voxel-based 
dose computation in the kerma approximation (Williamson 
1987), and similar approaches have also been developed for 
positron emitter distributions in proton therapy (Parodi et al 
2007). A specific track length estimator has been developed 
here to design a continuous process along the proton track 
that locally deposits the expected value of the prompt-γ 
emission (induced by proton inelastic scattering) that would 
have occurred if a large number of protons with the same 
incident energy had followed the same step (i.e. track 
element). First an elemental database of prompt-γ emission 
spectra is established in the clinical energy range of incident 
protons for all elements in the composition of human tissues. 
This database of the prompt-γ spectra is built offline with 
high statistics. Regarding the implementation of the prompt-
γ TLE MC tally, each proton deposits along its track the 
expectation of the prompt-γ spectra from the database 
according to the proton kinetic energy and the local material 
density and composition. All software developments have 
been carried out with the Gate/Geant4 toolkit. 
Results: A detailed statistical analysis is reported to 
characterize the dependency of the variance reduction on 
the geometrical (track length distribution) and physical 
(linear prompt-γ spectrum database) parameters. 
Benchmarking of the proposed technique with respect to an 
analogous MC technique is carried out. A large relative 
efficiency gain is reported, ca. 105. Such an efficiency gain 
could reduce the MC computing time of a full treatment from 
some weeks to less than one hour. Implementation issues are 
also addressed. 
Conclusions: This MC-based technique makes it possible to 
deal with complex situations such as heterogeneities for 
which proton straggling and secondary protons may have a 
decisive contribution. When considering translation to clinic, 
measurements for the prompt-γ spectrum database, or at 
least a sound calibration protocol of the simulated prompt-γ 
spectra, will have to be carried out. 
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Since the gastrin-releasing peptide receptor(GRPR) has been 
shown to be overexpressed in prostate cancer, bombesin 
which is the ligand of GRPR has been investigated to be a 
successful candidate for the peptide receptor 
radiotherapy(PRRT)[1]. The present study describes the 
imaging and therapeutic efficacy of the theranostic 
twins(68Ga/177Lu)-labeled bombesin derivatives for the PRRT 
of GRPR-overexpressing prostate tumors. 
A series of DOTA-conjugated bombesin derivatives were 
synthesized using a solid-phase synthesis. Competitive 
binding studies were performed for selecting a GRPR-
targeting peptide with high affinity. The selected peptide 
was labeled with 68Ga using the NaCl method for imaging[2], 
and labeled with 177Lu which was produced by the HANARO 
research reactor (thermal neutron flux of 1.8 × 1014 n·cm-2·s-
1) for therapy. The labeling yield was evaluated by iTLC-SG, 
and the PET/CT imaging and therapeutic efficacy of the 
radiolabeled peptides were evaluated using nude mice 
bearing PC-3 human prostate carcinoma xenograft. 
Hydrophilic-modified bombesin derivative showed a 
nanomolar binding affinity for GRPR. The peptide was labeled 
with the both radionuclides in high incorporation 
yields(>98%). 68Ga-labeled peptide was quickly cleared from 
the blood and clearly visualized in PC-3 tumors at 1 hr p.i. 
177Lu-labeled peptide were also rapidly accumulated in a PC-3 
tumor, and the % ID/g of the tumor was 12.42 ± 2.15 1 hr p.i. 
The radio-peptide significantly inhibited the tumor growth 
